Efficacy and Safety of Polyoxidonium, Nasal and Sublingual Spray, 6 mg/ml in Children Aged 1-12 Years With ARI
Status:
Completed
Trial end date:
2019-12-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is is to demonstrate superiority of Polyoxidonium, nasal and
sublingual spray, 6 mg/ml over placebo in children aged from 1 to 12 years with acute
respiratory viral infections. This is a multicenter prospective, randomized, double-blind,
placebo-controlled, parallel-group phase 3 study.